Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncotelic Therapeutics ( (OTLC) ) has issued an announcement.
On April 16, 2026, Oncotelic Therapeutics reported financial results for the year ended December 31, 2025, posting net income of about $249 million versus a $4.8 million loss in 2024, largely due to a non-cash $365.4 million uplift in the fair value of its GMP Bio joint venture investment, which also created a sizable deferred tax liability. The year was described as transformational, marked by progress across its JV pipeline, expansion of its PDAOAI research platform, and continued operation of its San Diego GMP manufacturing facility.
Operationally in 2025, the company completed its first combination immunotherapy Phase 1 trial of OT-101 with IL-2 in advanced solid tumors, initiated a Phase 2/3 OT-101 trial in pancreatic cancer, and advanced six Deciparticle-based nanoparticle candidates, including a clinical-stage everolimus program in Australia. It also formalized Sapu Bio and Sapu Nano as dual development arms, broadened AI-driven biomarker work including a novel everolimus sensitivity signature, and partnered with Shanghai Medicilon to support up to 20 IND projects, underscoring its push to build a scalable oncology development platform.
Spark’s Take on OTLC Stock
According to Spark, TipRanks’ AI Analyst, OTLC is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue characteristics, ongoing losses, and continued cash burn) combined with elevated balance-sheet leverage. Technicals also reflect recent weakness (negative MACD; price below key short/intermediate moving averages). Corporate actions around financing and debt milestones provide some support, but they are offset by ongoing dependence on capital markets and dilution risk; valuation signals are limited due to negative earnings.
To see Spark’s full report on OTLC stock, click here.
More about Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for orphan oncology indications, as well as antisense and small molecule injectable therapies for cancer. Through its joint venture GMP Biotechnology Limited and subsidiaries Sapu Bio and Sapu Nano, the company targets TGFβ2-driven biology, nanomedicine-based drug delivery via its Deciparticle platform, and AI-enabled biomarker discovery to support oncology drug development.
Average Trading Volume: 298,521
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.17M
See more insights into OTLC stock on TipRanks’ Stock Analysis page.